BLCO

BLCO

Bausch + Lomb Corp

Net 52.50%top 1%Rev 4.27%top 1%Net income grew 100% of yearsRevenue grew 100% of years1Y
Hold

Bausch + Lomb Corp develops, manufactures, and markets eye health products, including contact lenses, eye care supplements, and pharmaceuticals for conditions like glaucoma and dry eyes, as well as surgical devices for cataract and retinal treatments.

โš•๏ธ Healthcare NYSE Listed 2022 $ USD
$1,000 invested 1 year ago โ†’$1,217today

Score Overview

1 Year
Scoreโ€”
Net Growth52.50%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth4.27%
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-28x
Net Trend25%
Net Income Consistency
Rev Growth41.16%
Rev TrendEvery year
Revenue Consistency

See the full market ranking โ†’

Bausch + Lomb Corp fundamental performance

Across Bausch + Lomb Corp's full reported history, from 2022 to 2025, revenue grew from $ 3.76B to $ 5.10B and net income went from $ 6M to -$ 360M. Revenue increased in 100% of the years measured; net income in 25%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 16.76โ€”
1 Year2025-08-12
$ 13.7721.71%
All Time2022-05-06
$ 20.00-16.20%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 5.31B-$ 171M$ 367M
2025$ 5.10B-$ 360M$ 383M
2024$ 4.79B-$ 317M$ 305M
2023$ 4.14B-$ 260M$ 334M
IPO2022$ 3.76B$ 6M$ 380M

Explore beyond BLCO

You're looking at Bausch + Lomb Corp. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies